## Foghorn Therapeutics (FHTX) — deep dive using SEC filings & company disclosures ### Executive takeaway Foghorn is a clinical-stage precision oncology company built around its Gene Traffic Control® platform to study and drug targets in the chromatin regulatory system, with its lead clinical asset FHD-909 (LY4050784) in Phase 1 with partner Lilly and a broader preclinical “degrader” portfolio (CBP, EP300, ARID1B) that management is positioning for IND work in 2026. ["clinical stage, precision therapeutics biotechnology company"](0001628280-25-010933|0) ["FHD-909… first patient dosed in October 2024"](0001628280-25-010933|0) ["Selective CBP degrader… IND-ready in 2026"](0001193125-26-009885|4) Financially, the company is still loss-making, but it has relied on collaboration economics (especially Lilly), equity raises (May 2024) and, most recently, a January 2026 financing that management says extends cash runway into 1H 2028. ["Net loss… (86,620)"](0001628280-25-010933|0) ["net proceeds of $102.8 million"](0001628280-25-025312|0) ["cash… $208.9 million… extends cash into the first half of 2028"](0001193125-26-009885|4) --- ## 1) What the company is trying to do (and why “chromatin” matters) Foghorn’s core thesis is that abnormal gene expression can be “corrected” by selectively targeting the chromatin regulatory system, which it describes as implicated in ~50% of all cancers, creating a large target surface for precision medicines. ["chromatin regulatory system is implicated in approximately 50 percent of all cancers"](0001628280-25-010933|0) **How they claim to win (competitive framing in their own words):** - They position their Gene Traffic Control® platform as giving “integrated and mechanistic understanding” of the chromatin regulatory system’s components, enabling target identification/validation and drugging approaches across inhibitors, degraders, and transcription-factor disruptors. ["Gene Traffic Control® platform provides an integrated and mechanistic understanding"](0001628280-25-010933|0) - They emphasize being “modality agnostic” (inhibitors, degraders, disruptors) and “biology first,” which matters because chromatin targets can be hard to drug with a single modality. ["modality agnostic approach"](0001628280-25-010933|0) ["protein degraders… transcription factor disruptors"](0001628280-25-010933|0) --- ## 2) Pipeline map: programs, targets, and where value could accrue ### 2.1 “At-a-glance” pipeline table (from filings + January 2026 disclosure) | Program / asset | Modality / target | Stage | What to watch (company-stated) | |---|---|---|---| | FHD-909 (LY4050784) | Selective SMARCA2 inhibitor (chromatin remodeling/BAF complex) | Phase 1 (Lilly-led) ["Phase 1… clinical trial"](0001628280-25-010933|0) | Dose escalation progress; path to combination studies in front-line NSCLC (if Phase 1 supports it). ["Phase 1 trial on track"](0001193125-26-009885|4) ["anticipate evaluating… in combination studies"](0001193125-26-009885|4) | | Selective CBP degrader (e.g., CBPd-171 lead cited) | CBP degrader (selective) | Preclinical; aiming for IND-ready 2026 ["IND-ready anticipated in 2026"](0001193125-26-009885|4) | IND readiness timing; differentiation vs dual CBP/EP300 toxicity. ["dual inhibition… dose-limiting toxicities"](0001193125-26-009885|4) | | Selective EP300 degrader | EP300 degrader (selective) | Preclinical; IND-enabling studies expected 2026 ["IND-enabling studies expected in 2026"](0001193125-26-009885|4) | IND-enabling package; target indications (MM/DLBCL stated). ["focus in MM and DLBCL"](0001193125-26-009885|4) | | Selective ARID1B degrader | ARID1B degrader | Preclinical; aiming for in vivo PoC in 2026 ["proof of concept in 2026"](0001193125-26-009885|4) | In vivo proof-of-concept; selectivity and delivery approach. ["Selectively targets and degrades ARID1B"](0001193125-26-009885|4) | ### 2.2 Lead program deep dive: FHD-909 and the SMARCA4→SMARCA2 synthetic lethality idea In the 10‑K, Foghorn explains the biological logic: SMARCA4 is frequently mutated (including “up to 10% of NSCLC”), and loss of SMARCA4 can create dependency on SMARCA2, which can be exploited by selectively inhibiting SMARCA2. ["SMARCA4… up to 10 percent of NSCLC"](0001628280-25-010933|0) ["dependency on SMARCA2"](0001628280-25-010933|0) They describe FHD-909 as a first‑in‑class oral selective SMARCA2 inhibitor, and state it is in a Phase 1 open-label multi-center clinical trial, with first patient dosed in October 2024 (also reiterated in the 10‑K and Jan 2026 press release). ["FHD-909 is a first-in-class oral selective SMARCA2 inhibitor"](0001628280-25-010933|0) ["first patient was dosed… October 2024"](0001628280-25-010933|0) ["dosing of the first patient in October 2024"](0001193125-26-009885|4) **One nuance that matters economically:** the company states it transitioned FHD‑909 to Lilly in Q3 2023, triggering 50/50 cost share for SMARCA2 programs (until at least registrational trials). That changes cash burn sensitivity as the program scales. ["transitioned FHD-909 to Lilly… triggered the 50/50 cost share"](0001628280-25-010933|0) ["share in 50% of the costs until at least registrational trials"](0001628280-25-010933|0) --- ## 3) Collaboration economics: Lilly (core) and Merck (terminated) ### 3.1 Lilly collaboration: structure + revenue recognition implications From the 10‑K disclosures: - Upfront economics: $300.0 million upfront payment (cash) and a concurrent $80.0 million equity purchase by Lilly (Lilly SPA). ["upfront payment of $300.0 million"](0001628280-25-010933|0) ["issued and sold Lilly 4,000,000 shares… $80.0 million"](0001628280-25-010933|0) - They treat the Lilly collaboration + SPA as a combined arrangement for revenue accounting (notably allocating $37.8 million of the SPA proceeds to deferred revenue). ["allocated the excess consideration… to the Lilly Collaboration Agreement"](0001628280-22-013333|0) **Economics (high level):** For the SMARCA2 program and an additional undisclosed target, Foghorn describes 50/50 U.S. economics plus ex‑U.S. royalties starting in low double digits escalating into the twenties. ["share 50/50 in the U.S. economics"](0001628280-25-010933|0) ["royalties… starting in the low double-digit range and escalating into the twenties"](0001628280-25-010933|0) **Deferred revenue is still a big balance sheet item:** As of December 31, 2024, the company reports $280.1 million of deferred revenue related to Lilly remaining on the balance sheet (recognized over time based on cost-to-cost progress). ["we had $280.1 million of deferred revenue"](0001628280-25-010933|0) ["recognizes revenue using the cost-to-cost method"](0001628280-25-010933|0) ### 3.2 Merck collaboration: terminated and revenue “catch-up” Foghorn states Merck terminated the collaboration effective Nov 7, 2023, and Foghorn recognized the remaining deferred revenue as revenue in FY2023. ["terminating the Merck Collaboration Agreement effective November 7, 2023"](0001628280-25-010933|0) ["recognized the remaining $16.1 million of deferred revenue… as revenue"](0001628280-25-010933|0) --- ## 4) Financial profile and burn: what the statements say ### 4.1 Income statement snapshot (USD millions) > Scale note: filings present figures in thousands; table below is in **USD millions**. | Metric | FY2024 | FY2023 | |---|---:|---:| | Collaboration revenue | $22.60 ["Collaboration revenue… 22,602"](0001628280-25-010933|0) | $34.16 ["Collaboration revenue… 34,155"](0001628280-25-010933|0) | | R&D expense | $94.53 ["Research and development… 94,528"](0001628280-25-010933|0) | $109.69 ["Research and development… 109,689"](0001628280-25-010933|0) | | G&A expense | $28.36 ["General and administrative… 28,359"](0001628280-25-010933|0) | $32.37 ["General and administrative… 32,372"](0001628280-25-010933|0) | | Net loss | $(86.62) ["Net loss… (86,620)"](0001628280-25-010933|0) | $(98.43) ["Net loss… (98,426)"](0001628280-25-010933|0) | **Read-through:** Collaboration revenue is meaningful but not sufficient to cover operating cost base; the company is managing spend down versus FY2023, including lower headcount-related costs (per their narrative), while Lilly-partnered spend rose as FHD‑909 moved into Phase 1. ["decrease… due to decreased headcount"](0001628280-25-010933|0) ["increase in Lilly partnered programs… initiation of the Phase 1"](0001628280-25-010933|0) ### 4.2 R&D mix (what spend is actually going toward) | R&D category (USD millions) | FY2024 | FY2023 | |---|---:|---:| | FHD-286 | $11.14 ["FHD-286… 11,136"](0001628280-25-010933|0) | $11.25 ["FHD-286… 11,251"](0001628280-25-010933|0) | | Lilly partnered programs | $17.34 ["Lilly partnered programs… 17,335"](0001628280-25-010933|0) | $14.01 ["Lilly partnered programs… 14,013"](0001628280-25-010933|0) | | Early development & other external | $18.41 ["Early development… 18,407"](0001628280-25-010933|0) | $25.40 ["Early development… 25,399"](0001628280-25-010933|0) | | R&D personnel-related | $27.72 ["Personnel related… 27,718"](0001628280-25-010933|0) | $36.70 ["Personnel related… 36,702"](0001628280-25-010933|0) | | R&D facilities/IT/other | $19.93 ["Facilities and IT… 19,932"](0001628280-25-010933|0) | $22.32 ["Facilities and IT… 22,324"](0001628280-25-010933|0) | **What this implies (analyst framing, grounded in their disclosures):** - **Partnered costs are rising** (consistent with clinical-stage progression) while internal cost base is being reduced (lower personnel/facilities). ["increase in Lilly partnered programs… Phase 1"](0001628280-25-010933|0) ["decrease in personnel-related costs… decreased headcount"](0001628280-25-010933|0) - **Program pruning is real:** The 10‑K notes discontinuation of FHD‑286 independent development (AML combo) announced in Dec 2024. ["decision to discontinue the independent development of FHD-286"](0001628280-25-010933|0) ### 4.3 Balance sheet + liquidity (year-end and latest disclosed) | Metric | Dec 31, 2024 | Dec 31, 2023 | |---|---:|---:| | Cash & cash equivalents | $55.45m ["Cash and cash equivalents… 55,454"](0001628280-25-010933|0) | $80.34m ["Cash and cash equivalents… 80,336"](0001628280-25-010933|0) | | Marketable securities | $188.29m ["Marketable securities… 188,293"](0001628280-25-010933|0) | $153.72m ["Marketable securities… 153,721"](0001628280-25-010933|0) | | Deferred revenue (current + LT) | $280.06m (computed) ["Deferred revenue… 45,606"](0001628280-25-010933|0) ["Deferred revenue… 234,457"](0001628280-25-010933|0) | | Stockholders’ deficit | $(45.53)m ["Total stockholders’ deficit… (45,528)"](0001628280-25-010933|0) | $(77.19)m ["Total stockholders’ equity (deficit)… (77,190)"](0001628280-25-010933|0) | **Cash runway disclosure (most recent):** In January 2026 materials (8‑K exhibit), management states **cash, cash equivalents, and marketable securities of $208.9 million (unaudited, including financing proceeds)** and runway into **1H 2028**. ["cash, cash equivalents, and marketable securities of $208.9 million"](0001193125-26-009885|4) ["extends cash into the first half of 2028"](0001193125-26-009885|4) ### 4.4 Cash burn (operating cash flow) and a simple burn-rate lens | Metric | FY2024 | FY2023 | |---|---:|---:| | Net cash used in operating activities | $(100.41)m ["Net cash used in operating activities… (100,406)"](0001628280-25-010933|0) | $(118.11)m ["Net cash used in operating activities… (118,106)"](0001628280-25-010933|0) | | Avg monthly operating burn (computed) | $(8.37)m ["Net cash used… (100,406)"](0001628280-25-010933|0) | $(9.84)m ["Net cash used… (118,106)"](0001628280-25-010933|0) | --- ## 5) Capital structure & financing: dilution and “how they fund themselves” ### 5.1 The May 2024 public offering (context from 10‑Q) Foghorn describes a May 2024 offering that generated **$102.8 million net proceeds** and included **common shares plus pre-funded warrants**. ["offering closed… net proceeds of $102.8 million"](0001628280-25-025312|0) ["issued… pre-funded warrants"](0001628280-25-025312|0) ### 5.2 January 2026 equity financing (new disclosure; high signal) The Jan 2026 8‑K details a **$50.0 million** gross proceeds financing priced at **$6.71/share** (or $6.7099 per pre-funded warrant) plus two series of warrants (exercise prices $13.42 and $20.13), expected to close Jan 13, 2026. ["aggregate gross proceeds… approximately $50.0 million"](0001193125-26-009885|0) ["offering price… $6.71 per share"](0001193125-26-009885|0) ["expected to close on January 13, 2026"](0001193125-26-009885|0) --- ## 6) The risk register (pulled from their own risk framing) From the 10‑K’s risk factor summary, the dominant investor risks are typical for clinical-stage biotech but with a few Foghorn‑specific “tells”: - **Capital needs remain structural:** they explicitly say they will need substantial additional funding and could be forced to delay/reduce programs if financing is unavailable. ["We will need substantial additional funding"](0001628280-25-010933|0) - **Dependence on early-stage pipeline success:** heavy reliance on preclinical and Phase 1 assets. ["preclinical and Phase 1 clinical development"](0001628280-25-010933|0) - **Partner dependence / control risk:** partnered programs (notably Lilly) reduce unilateral control (development pace, prioritization). ["not able to exert unilateral control… collaboration with Lilly"](0001628280-25-010933|0) - **IP protection posture:** they explicitly note key aspects of Gene Traffic Control are trade secrets/know‑how (not patented), which increases leakage/replication risk. ["platform is not the subject of patent applications"](0001628280-25-010933|0) --- ## 7) “Choose-your-path” modules (interactive, no input required) ### Module A — Program diligence (FHD‑909) If you’re evaluating FHD‑909 as the valuation anchor, the diligence checklist is: 1) **Trial execution:** the company says Phase 1 is “advancing as planned” and “on track.” ["Phase 1… advancing as planned"](0001193125-26-009885|4) 2) **Combination strategy:** they point to preclinical synergy with pembrolizumab and KRAS inhibitors and potential front-line NSCLC combinations after dose escalation. ["Synergistic preclinical data… pembrolizumab and KRAS inhibitors"](0001193125-26-009885|4) ["anticipate evaluating… combination studies"](0001193125-26-009885|4) 3) **Economics/burn sensitivity:** 50/50 cost share with Lilly means Phase 1 expansion increases cash needs even though it’s partnered. ["share in 50% of the costs"](0001628280-25-010933|0) ### Module B — “Degrader platform” optionality If you’re underwriting the company as a multi‑shot platform rather than a single-asset story, the January 2026 update is a roadmap: CBP degrader IND-ready 2026; EP300 IND-enabling 2026; ARID1B in vivo PoC 2026. ["CBP degrader… IND-ready… 2026"](0001193125-26-009885|4) ["EP300… IND-enabling… 2026"](0001193125-26-009885|4) ["ARID1B… proof of concept in 2026"](0001193125-26-009885|4) ### Module C — Funding & runway robustness To stress-test runway, anchor to what’s disclosed (not assumptions): - FY2024 operating cash burn was ~$100.4m. ["Net cash used in operating activities… (100,406)"](0001628280-25-010933|0) - Management says post-financing liquidity is $208.9m and runway into 1H 2028. ["$208.9 million"](0001193125-26-009885|4) ["extends cash into the first half of 2028"](0001193125-26-009885|4) - The key “swing factors” they themselves highlight: scaling FHD‑909 clinical activity (partnered) and advancing preclinical programs toward INDs. ["expenses… increase… Phase 1 clinical trial of FHD-909… advance preclinical programs"](0001628280-25-025312|0) --- ### Source pack (primary filings/disclosures used) - FY2024 Form 10‑K (filed Mar 6, 2025): (0001628280-25-010933|0) - Q1 2025 Form 10‑Q (filed May 14, 2025): (0001628280-25-025312|0) - Jan 2026 financing + JPM update 8‑K and Exhibit 99.1: (0001193125-26-009885|0) (0001193125-26-009885|4) If you want an even deeper “model-like” view next, I can (a) build a compact 3‑statement historical table (FY2023–FY2024 + latest quarter), (b) extract and summarize the Lilly collaboration accounting/disclosure mechanics (deferred revenue roll-forward, performance obligation logic), and (c) map near-term catalysts implied by the company’s own “strategic objectives for 2026” language—using only the same filings above.

## Foghorn Therapeutics (FHTX) — deep dive using SEC filings & company disclosures ### Executive takeaway Foghorn is a clinical-stage precision oncology company built around its Gene Traffic Control® platform to study and drug targets in the chromatin regulatory system, with its lead clinical asset FHD-909 (LY4050784) in Phase 1 with partner Lilly and a broader preclinical “degrader” portfolio (CBP, EP300, ARID1B) that management is positioning for IND work in 2026. ["clinical stage, precision therapeutics biotechnology company"](0001628280-25-010933|0) ["FHD-909… first patient dosed in October 2024"](0001628280-25-010933|0) ["Selective CBP degrader… IND-ready in 2026"](0001193125-26-009885|4) Financially, the company is still loss-making, but it has relied on collaboration economics (especially Lilly), equity raises (May 2024) and, most recently, a January 2026 financing that management says extends cash runway into 1H 2028. ["Net loss… (86,620)"](0001628280-25-010933|0) ["net proceeds of $102.8 million"](0001628280-25-025312|0) ["cash… $208.9 million… extends cash into the first half of 2028"](0001193125-26-009885|4) --- ## 1) What the company is trying to do (and why “chromatin” matters) Foghorn’s core thesis is that abnormal gene expression can be “corrected” by selectively targeting the chromatin regulatory system, which it describes as implicated in ~50% of all cancers, creating a large target surface for precision medicines. ["chromatin regulatory system is implicated in approximately 50 percent of all cancers"](0001628280-25-010933|0) **How they claim to win (competitive framing in their own words):** - They position their Gene Traffic Control® platform as giving “integrated and mechanistic understanding” of the chromatin regulatory system’s components, enabling target identification/validation and drugging approaches across inhibitors, degraders, and transcription-factor disruptors. ["Gene Traffic Control® platform provides an integrated and mechanistic understanding"](0001628280-25-010933|0) - They emphasize being “modality agnostic” (inhibitors, degraders, disruptors) and “biology first,” which matters because chromatin targets can be hard to drug with a single modality. ["modality agnostic approach"](0001628280-25-010933|0) ["protein degraders… transcription factor disruptors"](0001628280-25-010933|0) --- ## 2) Pipeline map: programs, targets, and where value could accrue ### 2.1 “At-a-glance” pipeline table (from filings + January 2026 disclosure) | Program / asset | Modality / target | Stage | What to watch (company-stated) | |---|---|---|---| | FHD-909 (LY4050784) | Selective SMARCA2 inhibitor (chromatin remodeling/BAF complex) | Phase 1 (Lilly-led) ["Phase 1… clinical trial"](0001628280-25-010933|0) | Dose escalation progress; path to combination studies in front-line NSCLC (if Phase 1 supports it). ["Phase 1 trial on track"](0001193125-26-009885|4) ["anticipate evaluating… in combination studies"](0001193125-26-009885|4) | | Selective CBP degrader (e.g., CBPd-171 lead cited) | CBP degrader (selective) | Preclinical; aiming for IND-ready 2026 ["IND-ready anticipated in 2026"](0001193125-26-009885|4) | IND readiness timing; differentiation vs dual CBP/EP300 toxicity. ["dual inhibition… dose-limiting toxicities"](0001193125-26-009885|4) | | Selective EP300 degrader | EP300 degrader (selective) | Preclinical; IND-enabling studies expected 2026 ["IND-enabling studies expected in 2026"](0001193125-26-009885|4) | IND-enabling package; target indications (MM/DLBCL stated). ["focus in MM and DLBCL"](0001193125-26-009885|4) | | Selective ARID1B degrader | ARID1B degrader | Preclinical; aiming for in vivo PoC in 2026 ["proof of concept in 2026"](0001193125-26-009885|4) | In vivo proof-of-concept; selectivity and delivery approach. ["Selectively targets and degrades ARID1B"](0001193125-26-009885|4) | ### 2.2 Lead program deep dive: FHD-909 and the SMARCA4→SMARCA2 synthetic lethality idea In the 10‑K, Foghorn explains the biological logic: SMARCA4 is frequently mutated (including “up to 10% of NSCLC”), and loss of SMARCA4 can create dependency on SMARCA2, which can be exploited by selectively inhibiting SMARCA2. ["SMARCA4… up to 10 percent of NSCLC"](0001628280-25-010933|0) ["dependency on SMARCA2"](0001628280-25-010933|0) They describe FHD-909 as a first‑in‑class oral selective SMARCA2 inhibitor, and state it is in a Phase 1 open-label multi-center clinical trial, with first patient dosed in October 2024 (also reiterated in the 10‑K and Jan 2026 press release). ["FHD-909 is a first-in-class oral selective SMARCA2 inhibitor"](0001628280-25-010933|0) ["first patient was dosed… October 2024"](0001628280-25-010933|0) ["dosing of the first patient in October 2024"](0001193125-26-009885|4) **One nuance that matters economically:** the company states it transitioned FHD‑909 to Lilly in Q3 2023, triggering 50/50 cost share for SMARCA2 programs (until at least registrational trials). That changes cash burn sensitivity as the program scales. ["transitioned FHD-909 to Lilly… triggered the 50/50 cost share"](0001628280-25-010933|0) ["share in 50% of the costs until at least registrational trials"](0001628280-25-010933|0) --- ## 3) Collaboration economics: Lilly (core) and Merck (terminated) ### 3.1 Lilly collaboration: structure + revenue recognition implications From the 10‑K disclosures: - Upfront economics: $300.0 million upfront payment (cash) and a concurrent $80.0 million equity purchase by Lilly (Lilly SPA). ["upfront payment of $300.0 million"](0001628280-25-010933|0) ["issued and sold Lilly 4,000,000 shares… $80.0 million"](0001628280-25-010933|0) - They treat the Lilly collaboration + SPA as a combined arrangement for revenue accounting (notably allocating $37.8 million of the SPA proceeds to deferred revenue). ["allocated the excess consideration… to the Lilly Collaboration Agreement"](0001628280-22-013333|0) **Economics (high level):** For the SMARCA2 program and an additional undisclosed target, Foghorn describes 50/50 U.S. economics plus ex‑U.S. royalties starting in low double digits escalating into the twenties. ["share 50/50 in the U.S. economics"](0001628280-25-010933|0) ["royalties… starting in the low double-digit range and escalating into the twenties"](0001628280-25-010933|0) **Deferred revenue is still a big balance sheet item:** As of December 31, 2024, the company reports $280.1 million of deferred revenue related to Lilly remaining on the balance sheet (recognized over time based on cost-to-cost progress). ["we had $280.1 million of deferred revenue"](0001628280-25-010933|0) ["recognizes revenue using the cost-to-cost method"](0001628280-25-010933|0) ### 3.2 Merck collaboration: terminated and revenue “catch-up” Foghorn states Merck terminated the collaboration effective Nov 7, 2023, and Foghorn recognized the remaining deferred revenue as revenue in FY2023. ["terminating the Merck Collaboration Agreement effective November 7, 2023"](0001628280-25-010933|0) ["recognized the remaining $16.1 million of deferred revenue… as revenue"](0001628280-25-010933|0) --- ## 4) Financial profile and burn: what the statements say ### 4.1 Income statement snapshot (USD millions) > Scale note: filings present figures in thousands; table below is in **USD millions**. | Metric | FY2024 | FY2023 | |---|---:|---:| | Collaboration revenue | $22.60 ["Collaboration revenue… 22,602"](0001628280-25-010933|0) | $34.16 ["Collaboration revenue… 34,155"](0001628280-25-010933|0) | | R&D expense | $94.53 ["Research and development… 94,528"](0001628280-25-010933|0) | $109.69 ["Research and development… 109,689"](0001628280-25-010933|0) | | G&A expense | $28.36 ["General and administrative… 28,359"](0001628280-25-010933|0) | $32.37 ["General and administrative… 32,372"](0001628280-25-010933|0) | | Net loss | $(86.62) ["Net loss… (86,620)"](0001628280-25-010933|0) | $(98.43) ["Net loss… (98,426)"](0001628280-25-010933|0) | **Read-through:** Collaboration revenue is meaningful but not sufficient to cover operating cost base; the company is managing spend down versus FY2023, including lower headcount-related costs (per their narrative), while Lilly-partnered spend rose as FHD‑909 moved into Phase 1. ["decrease… due to decreased headcount"](0001628280-25-010933|0) ["increase in Lilly partnered programs… initiation of the Phase 1"](0001628280-25-010933|0) ### 4.2 R&D mix (what spend is actually going toward) | R&D category (USD millions) | FY2024 | FY2023 | |---|---:|---:| | FHD-286 | $11.14 ["FHD-286… 11,136"](0001628280-25-010933|0) | $11.25 ["FHD-286… 11,251"](0001628280-25-010933|0) | | Lilly partnered programs | $17.34 ["Lilly partnered programs… 17,335"](0001628280-25-010933|0) | $14.01 ["Lilly partnered programs… 14,013"](0001628280-25-010933|0) | | Early development & other external | $18.41 ["Early development… 18,407"](0001628280-25-010933|0) | $25.40 ["Early development… 25,399"](0001628280-25-010933|0) | | R&D personnel-related | $27.72 ["Personnel related… 27,718"](0001628280-25-010933|0) | $36.70 ["Personnel related… 36,702"](0001628280-25-010933|0) | | R&D facilities/IT/other | $19.93 ["Facilities and IT… 19,932"](0001628280-25-010933|0) | $22.32 ["Facilities and IT… 22,324"](0001628280-25-010933|0) | **What this implies (analyst framing, grounded in their disclosures):** - **Partnered costs are rising** (consistent with clinical-stage progression) while internal cost base is being reduced (lower personnel/facilities). ["increase in Lilly partnered programs… Phase 1"](0001628280-25-010933|0) ["decrease in personnel-related costs… decreased headcount"](0001628280-25-010933|0) - **Program pruning is real:** The 10‑K notes discontinuation of FHD‑286 independent development (AML combo) announced in Dec 2024. ["decision to discontinue the independent development of FHD-286"](0001628280-25-010933|0) ### 4.3 Balance sheet + liquidity (year-end and latest disclosed) | Metric | Dec 31, 2024 | Dec 31, 2023 | |---|---:|---:| | Cash & cash equivalents | $55.45m ["Cash and cash equivalents… 55,454"](0001628280-25-010933|0) | $80.34m ["Cash and cash equivalents… 80,336"](0001628280-25-010933|0) | | Marketable securities | $188.29m ["Marketable securities… 188,293"](0001628280-25-010933|0) | $153.72m ["Marketable securities… 153,721"](0001628280-25-010933|0) | | Deferred revenue (current + LT) | $280.06m (computed) ["Deferred revenue… 45,606"](0001628280-25-010933|0) ["Deferred revenue… 234,457"](0001628280-25-010933|0) | | Stockholders’ deficit | $(45.53)m ["Total stockholders’ deficit… (45,528)"](0001628280-25-010933|0) | $(77.19)m ["Total stockholders’ equity (deficit)… (77,190)"](0001628280-25-010933|0) | **Cash runway disclosure (most recent):** In January 2026 materials (8‑K exhibit), management states **cash, cash equivalents, and marketable securities of $208.9 million (unaudited, including financing proceeds)** and runway into **1H 2028**. ["cash, cash equivalents, and marketable securities of $208.9 million"](0001193125-26-009885|4) ["extends cash into the first half of 2028"](0001193125-26-009885|4) ### 4.4 Cash burn (operating cash flow) and a simple burn-rate lens | Metric | FY2024 | FY2023 | |---|---:|---:| | Net cash used in operating activities | $(100.41)m ["Net cash used in operating activities… (100,406)"](0001628280-25-010933|0) | $(118.11)m ["Net cash used in operating activities… (118,106)"](0001628280-25-010933|0) | | Avg monthly operating burn (computed) | $(8.37)m ["Net cash used… (100,406)"](0001628280-25-010933|0) | $(9.84)m ["Net cash used… (118,106)"](0001628280-25-010933|0) | --- ## 5) Capital structure & financing: dilution and “how they fund themselves” ### 5.1 The May 2024 public offering (context from 10‑Q) Foghorn describes a May 2024 offering that generated **$102.8 million net proceeds** and included **common shares plus pre-funded warrants**. ["offering closed… net proceeds of $102.8 million"](0001628280-25-025312|0) ["issued… pre-funded warrants"](0001628280-25-025312|0) ### 5.2 January 2026 equity financing (new disclosure; high signal) The Jan 2026 8‑K details a **$50.0 million** gross proceeds financing priced at **$6.71/share** (or $6.7099 per pre-funded warrant) plus two series of warrants (exercise prices $13.42 and $20.13), expected to close Jan 13, 2026. ["aggregate gross proceeds… approximately $50.0 million"](0001193125-26-009885|0) ["offering price… $6.71 per share"](0001193125-26-009885|0) ["expected to close on January 13, 2026"](0001193125-26-009885|0) --- ## 6) The risk register (pulled from their own risk framing) From the 10‑K’s risk factor summary, the dominant investor risks are typical for clinical-stage biotech but with a few Foghorn‑specific “tells”: - **Capital needs remain structural:** they explicitly say they will need substantial additional funding and could be forced to delay/reduce programs if financing is unavailable. ["We will need substantial additional funding"](0001628280-25-010933|0) - **Dependence on early-stage pipeline success:** heavy reliance on preclinical and Phase 1 assets. ["preclinical and Phase 1 clinical development"](0001628280-25-010933|0) - **Partner dependence / control risk:** partnered programs (notably Lilly) reduce unilateral control (development pace, prioritization). ["not able to exert unilateral control… collaboration with Lilly"](0001628280-25-010933|0) - **IP protection posture:** they explicitly note key aspects of Gene Traffic Control are trade secrets/know‑how (not patented), which increases leakage/replication risk. ["platform is not the subject of patent applications"](0001628280-25-010933|0) --- ## 7) “Choose-your-path” modules (interactive, no input required) ### Module A — Program diligence (FHD‑909) If you’re evaluating FHD‑909 as the valuation anchor, the diligence checklist is: 1) **Trial execution:** the company says Phase 1 is “advancing as planned” and “on track.” ["Phase 1… advancing as planned"](0001193125-26-009885|4) 2) **Combination strategy:** they point to preclinical synergy with pembrolizumab and KRAS inhibitors and potential front-line NSCLC combinations after dose escalation. ["Synergistic preclinical data… pembrolizumab and KRAS inhibitors"](0001193125-26-009885|4) ["anticipate evaluating… combination studies"](0001193125-26-009885|4) 3) **Economics/burn sensitivity:** 50/50 cost share with Lilly means Phase 1 expansion increases cash needs even though it’s partnered. ["share in 50% of the costs"](0001628280-25-010933|0) ### Module B — “Degrader platform” optionality If you’re underwriting the company as a multi‑shot platform rather than a single-asset story, the January 2026 update is a roadmap: CBP degrader IND-ready 2026; EP300 IND-enabling 2026; ARID1B in vivo PoC 2026. ["CBP degrader… IND-ready… 2026"](0001193125-26-009885|4) ["EP300… IND-enabling… 2026"](0001193125-26-009885|4) ["ARID1B… proof of concept in 2026"](0001193125-26-009885|4) ### Module C — Funding & runway robustness To stress-test runway, anchor to what’s disclosed (not assumptions): - FY2024 operating cash burn was ~$100.4m. ["Net cash used in operating activities… (100,406)"](0001628280-25-010933|0) - Management says post-financing liquidity is $208.9m and runway into 1H 2028. ["$208.9 million"](0001193125-26-009885|4) ["extends cash into the first half of 2028"](0001193125-26-009885|4) - The key “swing factors” they themselves highlight: scaling FHD‑909 clinical activity (partnered) and advancing preclinical programs toward INDs. ["expenses… increase… Phase 1 clinical trial of FHD-909… advance preclinical programs"](0001628280-25-025312|0) --- ### Source pack (primary filings/disclosures used) - FY2024 Form 10‑K (filed Mar 6, 2025): (0001628280-25-010933|0) - Q1 2025 Form 10‑Q (filed May 14, 2025): (0001628280-25-025312|0) - Jan 2026 financing + JPM update 8‑K and Exhibit 99.1: (0001193125-26-009885|0) (0001193125-26-009885|4) If you want an even deeper “model-like” view next, I can (a) build a compact 3‑statement historical table (FY2023–FY2024 + latest quarter), (b) extract and summarize the Lilly collaboration accounting/disclosure mechanics (deferred revenue roll-forward, performance obligation logic), and (c) map near-term catalysts implied by the company’s own “strategic objectives for 2026” language—using only the same filings above.